Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRP104 in Adults With ADHD
NCT00334880Phase 3Completed
- Sponsor
- New River Pharmaceuticals
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), sponsored by New River Pharmaceuticals. Started May 2006; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00334880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00334880.